Advertisement
Research Article

Immunopotentiation of Trivalent Influenza Vaccine When Given with VAX102, a Recombinant Influenza M2e Vaccine Fused to the TLR5 Ligand Flagellin

  • H. Keipp Talbot mail,

    keipp.talbot@vanderbilt.edu

    Affiliation: Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America

    X
  • Michael T. Rock,

    Affiliation: Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America

    X
  • Casey Johnson,

    Affiliation: Johnson County Clin-Trials, Lenexa, Kansas, United States of America

    X
  • Lynda Tussey,

    Affiliation: VaxInnate Corporation, Cranbury, New Jersey, United States of America

    X
  • Uma Kavita,

    Affiliation: VaxInnate Corporation, Cranbury, New Jersey, United States of America

    X
  • Anita Shanker,

    Affiliation: Health Decisions, Durham, North Carolina, United States of America

    X
  • Alan R. Shaw,

    Affiliation: VaxInnate Corporation, Cranbury, New Jersey, United States of America

    X
  • David N. Taylor

    Affiliation: VaxInnate Corporation, Cranbury, New Jersey, United States of America

    X
  • Published: December 28, 2010
  • DOI: 10.1371/journal.pone.0014442

About the Authors

H. Keipp Talbot
Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
Michael T. Rock
Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
Casey Johnson
Johnson County Clin-Trials, Lenexa, Kansas, United States of America
Lynda Tussey, Uma Kavita, Alan R. Shaw, David N. Taylor
VaxInnate Corporation, Cranbury, New Jersey, United States of America
Anita Shanker
Health Decisions, Durham, North Carolina, United States of America

Corresponding Author

Email: keipp.talbot@vanderbilt.edu

Competing Interests

HKBT has received research funding from Protein Sciences, VaxInnate, Sanofi Pasteur and Wyeth. MR has no conflicts of interest. Casey Johnson works for Johnson County Clin-Trials, which was hired by VaxInnate. Anita Shanker works for Health Decisions, which was hired by VaxInnate for data management. Lynda Tussey, Uma Kavita, Alan Shaw and David Taylor work for VaxInnate. This will not interfere with sharing data.

Author Contributions

Conceived and designed the experiments: HKT MTR LT UK A. Shaw DNT. Performed the experiments: HKT MTR CJ LT UK. Analyzed the data: HKT LT UK A. Shanker DNT. Wrote the paper: HKT MTR LT UK A. Shanker A. Shaw DNT.